Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on May 02, 2022 10:14am
104 Views
Post# 34647337

RE:RE:RE:Nash Phase 3 Trial

RE:RE:RE:Nash Phase 3 Trial

At this point a NASH ph3 seems like a bigger miracle to me than Oncology Good News only because there's an obvious path to the oncology data

Personally my occasional prayer is for a (smallish) multi-arm Ph2 in NASH. Where Novo Nordisk have looked into semaglutide combo'd with rGH preclinically. Decided the MOAs are compatible but rejected rGH because of safety concerns in adults and instead turn to GHRH. We end up with an Egrifta arm and a combo arm. We fill the hole in the ph2 data and get a bonus combo with an exciting drug thrown in for good measure. No material grounds to think this would happen, just my little fantasy. I think if the Pharma combos start reading out with good news then combo might seem like the best (only) game in town.


palinc2000 wrote:

I am also a Christian and I am not only for resurrections in Nash  but also for miracles in Oncology......However as you know God helps those who help themselves ...That's why I keep pushing for better execution in the commercial activities.... I really like the renewed focus on Hiv related ilnesses as demonstrated by the last job posted ....
Unfortunately the organisation being built by Paul mostly from scratch has gone un noticed so far but the renewed THTX is taking shape .... Someday we will see the Light and that day is not far away...

 

SPCEO1 wrote: As a Christian, I am all for resurrections! Let's hope we can get one with the NASH phase III trial but it will be a bonus if it happens as far as I am concerned.
 

 

palinc2000 wrote: https://youtu.be/krjQYwWi7ZU

 




<< Previous
Bullboard Posts
Next >>